At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 148 enrolled
Drug / intervention
recombinant human hyaluronidasedrug
Likely dose
recombinant human hyaluronidase 150 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subcutaneous Rehydration With Hylenex Compared to Intravenous Rehydration in Infants and Young Children With Mild to Moderate Dehydration
In Brief
A Phase 4 clinical trial evaluating recombinant human hyaluronidase for Dehydration. Completed, enrolled 148 participants across 25 sites.
Detailed Summary
Randomized (1:1 ratio) study of subcutaneous (SC) versus intravenous (IV) fluid rehydration in mildly to moderately dehydrated pediatric patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDehydration
CountriesUnited States
CollaboratorsBaxter Healthcare Corporation
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionNov 2009
Study CompletionDec 2009
TodayJul 2026
First PostedOct 16, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.7 years ago
Interventions
recombinant human hyaluronidasedrug
150 Units in 1 mL